Software programs will continue to play vital role for the National Toxicology Program
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Malaria is one of the most significant causes of childhood mortality, but disease control efforts are threatened by resistance of the Plasmodium parasite to current therapies.
Simulations Plus Reports Third Quarter FY2015 Financial Results
Revenues up 58.9%, Net Income up 41.7%
Board declares dividend of $0.05/share
TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells
Prostate cancer progression was associated with tumorigenic signaling activated by proinflammatory mediators. However, the etiology of these events remains elusive.
Simulations Plus Sets Date for 3rd Quarter 2015 Earnings Release and Conference Call
Conference call to be on Monday, July 13, 2015, at 4:15 p.m. EDT
Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs
During the last decades, the importance of modeling and simulation in clinical drug development, with the goal to qualitatively and quantitatively assess and understand mechanisms of pharmacokinetic processes...
Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models
In vitro and in vivo experimental models are frequently used to assess a new chemical entity's (NCE) biopharmaceutical performance risk for food effect (FE) in humans.
Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems
The objective of this study was to develop a level A in vitro-in vivo correlation (IVIVC) for drug-in-adhesive (DIA) type estradiol transdermaldrug delivery systems (TDDS).
Virtual tests for new therapies (From Bayer Research)
When researchers design a new drug product, they have to know exactly what will happen to the active ingredient once it is inside the body.
Prediction of Oral Bioavailability in silico
A database of 62 drugs including oral bioavailability (F%) and dose was constructed: All compounds’ reported major clearance pathways (MCP) were CYP-mediated, For 43 drugs with more than one reported value...
Applications and considerations of drug exposure predictions in pediatric
This GastroPlus™ User Group webinar will focus on special considerations when performing pediatric PBPK modeling in GastroPlus™.
What’s New in ADMET Predictor™ 7.2?
Two new models, fraction unbound to liver microsomes and unbound human liver microsomal intrinsic clearance, were added to ADMET Predictor 7.2.
Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment
Risk assessment methodologies in toxicology have remained largely unchanged for decades. The default approach uses high dose animal studies, together with human exposure estimates...
Toward Progressive Reporting of Modeling and Simulation Results – Part 1: Analysis of KIWI™ Metadata
Technical reports for pharmacometric modeling provide comprehensive documentation, typically including data assembly methods and disposition, modeling strategy, and analysis results. These reports, however…
Marine Drug Discovery Database (MDDD) – A Database of In silico Predicted Physico-Chemical, Drug Likeness and Toxicological Properties of Marine Compounds
Marine is one of the largest and richest natural resources of bioactive compounds.
What’s New In GastroPlus™ 9.0?
This informative webinar covers the new features in the latest version of GastroPlus™ 9.0.
Simulations Plus Releases ADMET Predictor Version 7.2
Enhances synergy between predicted properties and GastroPlus™ Version 9.0 modeling capabilities